CASP6 and glioblastoma: Exposure to 50 μM enzalutamide, respectively, enhanced caspase-6 activities by 133% and 76% in human TMZ-sensitive U87 MG and TMZ-resistant U87 MG-R glioblastoma cells (Figure 6B).